TY  - GEN
AU  - Garassino,Marina Chiara
AU  - Martelli,Olga
AU  - Broggini,Massimo
AU  - Farina,Gabriella
AU  - Veronese,Silvio
AU  - Rulli,Eliana
AU  - Bianchi,Filippo
AU  - Bettini,Anna
AU  - Longo,Flavia
AU  - Moscetti,Luca
AU  - Tomirotti,Maurizio
AU  - Marabese,Mirko
AU  - Ganzinelli,Monica
AU  - Lauricella,Calogero
AU  - Labianca,Roberto
AU  - Floriani,Irene
AU  - Giaccone,Giuseppe
AU  - Torri,Valter
AU  - Scanni,Alberto
AU  - Marsoni,Silvia
TI  - Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
SN  - 1474-5488
PY  - 2013///1104
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins
KW  - genetics
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Quinazolines
KW  - Taxoids
KW  - ras Proteins
N1  - Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(13)70310-3
ER  -